

# HESTER BIOSCIENCE

## INVESTMENT REPORT



---

+91 7092358609  
[www.settypicks.com](http://www.settypicks.com)  
[settypicks@gmail.com](mailto:settypicks@gmail.com)

---

June 2021  
O.R.NIRMAL  
Chief Executive Officer



# COMPANY PROFILE

Hester Biosciences Limited is one of India's leading animal healthcare companies and is the second largest poultry vaccine manufacturer in the country. Founded by Mr. Rajiv Gandhi, Hester began its journey in 1987. Over the years, it has transformed from a small proprietary trading business into Asia's largest one-stop animal biological manufacturing facility. We now have a strategic presence in over 30 countries, while focusing on key market needs in India, Nepal and Tanzania. We have also partnered with various organisations over the years including Bill & Melinda Gates Foundation, GALVmed, Golchha Organisation, and our latest foray into the Egyptian market with Novapharma, to name a few

# 2021 HESTER PLANT

---

Hester Biosciences Nepal

Private Limited (HBNPL)

65% stake

Engaged in manufacturing of animal vaccines in Nepal

Texas Lifesciences Private

Limited (Texas Lifesciences)

54.80% stake

Engaged in manufacturing and supplying of pharma formulations, tablets, capsules, powder and oral liquid for human and veterinary markets

Hester Biosciences Africa

Limited (HBAL)

100% stake

---

Manufacturing plant for animal vaccines is being set up in Tanzania

Hester Biosciences Kenya

Limited (HBKL)

100% stake

Engaged in the trading of veterinary vaccines and animal health product in Kenya

Hester Biosciences

Tanzania Limited (HBTL)

98.10% stake

Engaged in the trading of veterinary vaccines and animal health product in Tanzania and other regions of Africa involved).

2021

# STATISTICS

**35%**

## MARKET SHARE

Second largest poultry vaccine manufacturer in INDIA. Manufacturer of other animal vaccine.

**20 MILLION**

## TOTAL PRODUCTION

Hester Biosciences will produce 20 million doses of Bharat Biotech's COVID-19 vaccine Covaxin per month from August 2021

**1.2 BILLION**

## VACCINE

1.2 billion doses of live and inactivated vaccines are produced annually in NEPAL plant alone.

**25 COUNTRIES**

## GLOBAL PRESENCE

Extensive global presence over 25 countries and reaching new market day by day

**170 CRORES**

## EARNINGS

Turnover of hester bioscience for the year 2019-2020.

# Financial Summary

## Territorial Revenue

Most of our sales come from INDIA. Management is trying to diversify the product portfolio and expand its business in AFRICA. Africa is a untapped market so scope for growth is high when compared to other countries.

To be specific, the breakdown is:

**84%**

**INDIA**

**8%**

**NEPAL**

**1.4%**

**AFRICA**

**6.36%**

**OTHERS**

## REVENUE BY SEGMENT

**71%**

**POULTRY  
HEALTHCARE**

**18%**

**ANIMAL  
HEALTHCARE**

**11%**

**OTHERS**

Revenue earned by hester bioscience from different segment for the year 2020-2021. Most of its revenue come from poultry healthcare. Company aims to expand its business in other vertices



# HESTER

## SETTY PICKS

### ● **BUYING PRICE**

Price for accumulation

**BUY RS 2000-2300**

**CMP - RS200**

**ADD ON DIPS BELOW RS 2000**

### ● **TARGET PRICE**

**SELL PRICE -RS4200**

**horizon 2 years**

### ● **OUR VIEW**

**WE ARE Bullish ON HESTER BIOSCIENCE**

**WE BIELEVE IN NEXT 10 YEARS PEOPLE CONSUMING MEAT AND DAIRY PRODUCT WILL INCREASE WHICH INCREASE NO OF FARM ANIMALS WHICH WILL INCREASE SALE OF VACCINE**